MAY 2015 ARTICLE LIST >>
PharmaTutor (May- 2015)
Print-ISSN: 2394 - 6679
e-ISSN: 2347 - 7881
(Volume 3, Issue 5)
Received On: 16/12/2014; Accepted On: 19/02/2015; Published On: 01/05/2015
AUTHORS: Akash M Patel*, Viren N Sisodiya
* Faculty of Pharmacy,
Dharmsinh Desai University, Nadiad-387001, Gujarat
aku.pharmacy@gmail.com
ABSTRACT: Taste is an important factor in the development of dosage form. The problem of bitter and obnoxious taste of drug in pediatric patient can create a bad psychological effect on mind. The purpose of this research was to mask the intensely bitter taste of Linezolid using ion exchange resin and to formulate the dry syrup of the taste masked drug. When suspension is swallowed the bitter taste of the drug may not be felt as ion exchange resin does not release the drug at salivary pH. When it comes in contact with acidic environment of stomach, the complex will be broken down releasing the drug which may then absorbed. Batch method was used for formation of drug resin complex. Various ion exchange resin like different grade of kyron and indion 214 were used for masking the bitter taste. Optimization of drug loading was carried out. Indion 214 was selected as a optimized resin with 84.47 % drug loading. Dry syrup was made using suspending agent like gellan gum, guar gum and CMC and evaluated for various parameters like colour, odour, taste, viscosity, sedimentation volume, redispersibility, % drug content, drug release. By evaluating all the parameter the batch formulation contained guar gum 3 % was the best one amongst all the other formulations.
How to cite this article: AM Patel, VN Sisodiya; Formulation and Evaluation of Dry Syrup Containing Linezolid; PharmaTutor; 2015; 3(5); 42-48
[ABSTRACT WITH CITATION] [VIEW AS HTML]
REFERENCES:
1. Zyvox® (linezolid) [package insert]. New York, NY: Pfizer Inc., America; July 2006.
2. Lacy C, Armstrong L, Goldman M, Lance L, Linezolid, Drug Information Handbook Lexi-Comp Inc., 2008-2009 17th Edn, 927-929.
3. Barnhill AE, Brewer MT, Carlson SA; Adverse effects of antimicrobials via predictable or idiosyncratic inhibition of host mitochondrial components; Antimicrob Agents and Chemotherapy 2012; 56(8); 4046–4051
4. Shinabarger DL, Marotti KR, Murray RW, Lin AH, Melchior EP, Swaney SM, et al; Mechanism of action of oxazolidinones: effect of linezolid and eperezolid on translation reactions; Antimicrob Agents Chemother; 1997; 41(10); 2132–2136
5. Wang Rui Liang Beibei, Cai Yun, Chen Mengli, Bai Nan, Yu Xuhong; Linezolid versus vancomycin for the treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials; Int J Antimicrob Agents; 2010; 35(1); 3–12.
6. Shalini Sharma, Shaila Lewis; Taste Masking Technologies A Review; Int J Pharm and Pharma Sci; 2010; 2(2); 6-13
7. Harwood RJ, Rowe RC, Sheskey PJ and Weller PJ. In Handbook of Pharmaceutical Excipients; Pharma Press, London, UK; 2003; 6th Edn; 701.
8. Harwood RJ, Rowe RC, Sheskey PJ and Weller PJ. In Handbook of Pharmaceutical Excipients; Pharma Press, London, UK; 2003; 6th Edn; 687
9. Harwood RJ, Rowe RC, Sheskey PJ and Weller PJ. In Handbook of Pharmaceutical Excipients; Pharma Press, London, UK; 2003; 6th Edn; 662.
10. J.L.Munoz Bellido, M.N. Gutierrez Zufiaurre,F.J. Sanchez Hernandez, G.Yagüe Guirao, M. Segovia Hernandez, J.A. Garc?a-Rodr?guez; In vitro activity of linezolid, synercid and telithromcin against genetically defined high level fluoroquinolone-resistant methicillin resistant Staphylococcus aureus; Int J Antimicro Agents; 2002; 20(1); 61-68
11. Richard G. Wunderink, Sue K. Cammarata, Thomas H. Oliphant, Marin H. Kollef; The Linezolid Nosocomial Pneumonia Study Group; Methodist Healthcare Memphis; 2003; 980-988.
12. Lories I. Bebawy; Stability-indicating methods for the determination of linezolid in the presence of its alkaline-induced degradation products; Talanta; 2003; 60(5); 945-953.
13. Federico Pea, Pierluigi Viale, Manuela Lugano, Federica Pavan, Luigia Scudeller, Giorgio Della Rocca, and Mario Furlanut; Linezolid Disposition After Standard Dosages in Critically Ill Patients Undergoing Continuous Venovenous Hemofiltration: A Report of 2 Cases; American J Kidney Diseases; 2004; 44(6); 1097-1102.
14. Prasanna Kumari. J, Ramarao.T, Jayaveera.K.N; Review on bilayer floating tablets – a novel approach to Gastroretenttion; Int J Antimicrob Pharma Res; 2013; 3(5); 4105-4122
15. K.Sai Madhav Reddy, Laxmidhar Sahoo, Dr.G.Kamalakar Reddy, L.Vamsi Krishna; Formulation and Evaluation of Immediate Release Tablets of Linezolid; Int J Pharma & Bio Archives; 2011; 2(4); 1230-1235.
.png)
